New Frontiers in Reducing CVD Risk
2025 Section 3-Accredited Self-Assessment Program.
This program explores the latest advancements in cardiovascular risk management, focusing on key risk factors for cardiovascular events and mortality. Participants will review clinical evidence supporting the use of GLP-1 receptor agonists (GLP-1RA) in managing ASCVD and HFpEF and discuss best practices for integrating these new therapeutic modalities into comprehensive cardiovascular risk strategies.